U.S. News Room
January 15, 2021
ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive Advanced Gastric Cancer
Download
January 13, 2021
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung Cancer
December 14, 2020
TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC with Actionable Genomic Alterations
Download
December 14, 2020
TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Patients with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Download
December 10, 2020
ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer
Download
December 10, 2020
Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer Symposium
Download
November 17, 2020
Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS
Download
November 12, 2020
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with Cancer
Download
November 02, 2020
DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy
Download
October 28, 2020
ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer
Download
October 22, 2020
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells
Download
September 25, 2020
ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
Download
September 18, 2020
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020
Download
September 14, 2020
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer
Download
September 09, 2020
Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be Presented at 2020 ESMO Annual Meeting
Download
August 06, 2020
Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
Download
July 27, 2020
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Download
July 22, 2020
Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan
Download
July 01, 2020
Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer
Download
May 29, 2020
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial
Download
May 29, 2020
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
Download
May 29, 2020
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
Download
May 29, 2020
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
Download
May 29, 2020
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
Download
May 28, 2020
Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline
Download
May 25, 2020
Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
Download
May 22, 2020
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute
Download
May 18, 2020
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Download
May 15, 2020
Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR Virtual Annual Meeting II
Download
May 13, 2020
Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting
Download
May 11, 2020
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer
Download
May 07, 2020
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
Download
March 30, 2020
Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan
Download
March 25, 2020
ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
Download
January 27, 2020
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
Download